ERDERA Clinical Trial Call 2026 – Pre-announcement

1:1
Pre-announcement describing scope, eligibility and indicative timeline for the ERDERA Clinical Trial Call 2026, expected to open on 1 July 2026.

This pre-announcement outlines the upcoming ERDERA Clinical Trial Call 2026 (ECTC), expected to open on 1 July 2026, to support multinational, GCP-compliant Phase I, Phase I/II and Phase II interventional clinical trials in rare diseases.

It summarises priority areas, eligible applicants, eligible interventions (including small molecules, ATMPs and biologics), expected eligible countries and an indicative multi-stage application process, including an information webinar on 6 July 2026 (15:00–17:00 CEST).

publication

You might also be interested in

The multicentre observational study analysed 661 assessments from 219 people with SCA27B to examine disease progression, clinical outcome metrics and demographic or genetic modifiers.
At the “Advancement of Treatments for Rare Diseases” conference in Nicosia, European and national policymakers joined clinicians, researchers, regulators, industry representatives and patient advocates to examine how stronger coordination can translate scientific progress into better prevention, diagnosis, treatment and access to care for people living with rare diseases.
Call text draft setting out rules, eligibility and staged application process for the ERDERA Clinical Trial Call 2026.